Idéal Investisseur
Français English
CAC 40 : Market open
8 171,43 pts
-1.05%


Last updated : 26/05/2026 - 12h01
🏠 Home   ➤    Stock news

Guerbet: Antoine Fady Becomes Chairman of the Board

On Friday, Guerbet announced a reshuffling of its board of directors following its general assembly on May 22, 2026. Antoine Fady has been appointed as the chairman of the board, with three new directors representing the majority shareholder also joining.


Guerbet: Antoine Fady Becomes Chairman of the Board

Antoine Fady as Chairman of the Board

Antoine Fady has been appointed as an independent director and chairman of the board of directors of Guerbet, effective immediately. This appointment concludes his role as a censor, which he has held since March 11, 2026. A graduate engineer from the École nationale supérieure des Mines de Saint-Étienne and holder of an MBA from INSEAD, Fady has over ten years of experience as the CEO of Flint Group. He has also held various senior management positions at ICI and Akzo Nobel, particularly in the paints and coatings activities in Europe. His career also includes governance experience as a non-executive director and board chairman, including at Roquette (current mandate) and XSYS (chairman of the board from 2021 to 2024).

Three New Directors Representing the Majority Shareholder

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
Before 9 AM every morning Euronext data AI-powered analysis

The general assembly appointed three new directors representing the majority shareholder. Emmanuelle Louvet replaces Nicolas Louvet, whose term has expired. Vincent Dagommer replaces Marc Massiot, who resigned. Olivier Guerbet replaces Carine Dagommer, whose term has also expired. The board of directors of Guerbet now consists of nine members: Antoine Fady (chairman of the board, independent director), Vincent Dagommer, Eric Drapé (independent director), Marie de la Simone (employee director), Eric Guerbet, Olivier Guerbet, Céline Lamort, Michèle Lesieur (independent director), and Emmanuelle Louvet.

Related


Sector Industrie Pharmaceutique et Biotechnologie Industrie Pharmaceutique


Assurance vie

Context

Period
  • Period: 1T2026
Key reported figures
  • Revenue: 177.4M€
Guidance from the release
  • Le chiffre d'affaires du premier trimestre s'établit à 177,4 M€, en léger repli.
Risks mentioned
  • Dépréciation des devises impacte le chiffre d'affaires.
  • Baisse des volumes sur le site de Raleigh.
  • Ralentissement du niveau de libération des lots produits à Raleigh.
Opportunities identified
  • Augmentation des ventes en EMEA de 4,5 %.
  • Hausse de 6,0 % des ventes en Asie sur la période.
  • Amélioration de la situation en France.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
Avant 9h00 1000+ inscrits 100% gratuit